Literature DB >> 26729748

The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study.

Anne M Durkan1, Siah Kim1, Jonathan Craig1, Elizabeth Elliott2.   

Abstract

BACKGROUND: Atypical haemolytic uraemic syndrome (aHUS) accounts for ∼10% of all cases of HUS and is often due to complement dysregulation. The short-term outcomes for this disease are established, but there are limited long-term data. The long-term outcomes of a comprehensive nationwide cohort of children with aHUS are presented here.
METHODS: The Australian Paediatric Surveillance Unit prospectively collected data on all cases of HUS in children seen by paediatricians between 1994 and 2001. Patients with aHUS were followed-up with a written questionnaire to the treating clinician at 1 year and again before transition to adult services or at last known follow-up.
RESULTS: There were 146 reported cases of HUS, of which 14 were aHUS. Ten children required dialysis at first presentation, including two who died and three who did not recover renal function. The disease was relapsing in all but one who survived the presenting episode, with most relapses occurring in the first 12 months. At 1 year, one child was lost to follow-up. Nine of the remaining 11 patients were dialysis dependent. Thirteen kidneys were transplanted into eight children. There was disease recurrence in eight kidneys, which resulted in graft loss in seven. There were three further deaths 1.7, 6.7 and 16.1 years after the initial presentation. Five children developed neurological complications and two had cardiac complications, largely at the time of onset of the disease.
CONCLUSIONS: aHUS is a rare but devastating disease with very high mortality and morbidity that extends beyond the initial presentation period. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Epidemiology; Nephrology; Outcomes research

Mesh:

Year:  2016        PMID: 26729748     DOI: 10.1136/archdischild-2015-309471

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  7 in total

1.  Complement factor B mutation-associated aHUS and myocardial infarction.

Authors:  Natália Noronha; Filipa Dias Costa; Andrea Dias; Alexandra Dinis
Journal:  BMJ Case Rep       Date:  2017-07-14

2.  Atypical presentation of atypical haemolytic uraemic syndrome.

Authors:  Ratna Basak; Xiaotong Wang; Caitlin Keane; Robert Woroniecki
Journal:  BMJ Case Rep       Date:  2018-02-11

3.  Clinical features in a series of 258 Japanese pediatric patients with thrombotic microangiopathy.

Authors:  Akira Ashida; Hideki Matsumura; Toshihiro Sawai; Rika Fujimaru; Yuko Fujii; Akihiko Shirasu; Hyogo Nakakura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2018-01-19       Impact factor: 2.801

4.  Eculizumab Dosing in Infants.

Authors:  M Kobrzynski; B Wile; S S Huang; G Filler
Journal:  Indian J Nephrol       Date:  2018 Jan-Feb

Review 5.  Advances in our understanding of the pathogenesis of hemolytic uremic syndromes.

Authors:  E E Bowen; R J Coward
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-22

Review 6.  Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review.

Authors:  Kevin Yan; Kamal Desai; Lakshmi Gullapalli; Eric Druyts; Chakrapani Balijepalli
Journal:  Clin Epidemiol       Date:  2020-03-12       Impact factor: 4.790

7.  Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality.

Authors:  Gianluigi Ardissino; Selena Longhi; Luigi Porcaro; Giulia Pintarelli; Bice Strumbo; Valentina Capone; Donata Cresseri; Giulia Loffredo; Francesca Tel; Stefania Salardi; Martina Sgarbanti; Laura Martelli; Evangeline Millicent Rodrigues; Nicolò Borsa-Ghiringhelli; Giovanni Montini; Manuela Seia; Massimo Cugno; Fabio Carfagna; Dario Consonni; Silvana Tedeschi
Journal:  Kidney Int Rep       Date:  2021-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.